National Institute for Health and Clinical Excellence (NICE)
Patients with rare blood disorders to receive new treatment option, says NICE
Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen following guidance from NICE.
In final guidance published yesterday (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Currently, people with symptomatic PNH or aHUS only have one treatment option available on the NHS, eculizumab, which was also recommended by NICE and is delivered intravenously every 2 weeks.
The new guidance means that patients with either disease will now be eligible for treatment with ravulizumab, which is delivered every 8 weeks. Patient experts stated that this increase in time between treatments may improve the quality of life for people with the rare blood disorders, increasing their independence and psychological wellbeing.
Clinical trial evidence showed that, in people with PNH, treatment with ravulizumab is at least as clinically effective as eculizumab, and was found to cause fewer episodes of breakthrough haemolysis, a symptom of PNH, reducing the number of hospital admissions and the need for blood transfusions.
Indirect comparisons of ravulizumab with eculizumab for people with aHUS similarly suggest that ravulizumab is as effective for treating aHUS.
Ravulizumab is also cost saving for the NHS in both patient populations and is therefore considered an effective use of NHS resources, and is recommended for routine use on the NHS. Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, yesterday said:
“Living with a rare blood condition can be both physically and mentally challenging, especially when frequent treatment is required.
“We are pleased to be able to recommend ravulizumab for people who have paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome.
“We are hopeful that the increased time between doses with this new treatment will lead to a better quality of life for these individuals and their loved ones.”
PNH is a rare blood disorder characterised by an excessive breakdown in red blood cells, which can lead to anaemia, kidney problems, and blood clots in the blood vessels.
Also rare, aHUS causes blood clots in small blood vessels, which can lead to organ damage and significant kidney impairment, thrombosis, heart failure and brain injury.
Both are chronic conditions which can be life-threatening when left untreated.
Blake Dark, commercial medicines director at NHS England yesterday said:
“Hundreds of NHS patients will have access to ravulizumab, a potentially life-improving treatment that could give patients with rare blood disorders a greater quality of life, more independence with fewer hospital admissions and blood transfusions throughout their lifetime.
“The NHS is here for everyone, whether it’s providing COVID-19 vaccines for millions or securing access to innovative new medicines, and adopting new treatments such as ravulizumab demonstrates how the NHS can improve the lives of people suffering with rare chronic conditions and also secure the best value for the taxpayer.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Patients with rare bile duct cancer set to benefit from life extending treatment22/07/2021 13:15:00
Some people who have a rare form of bile duct cancer are set to benefit from life-extending treatment
A new approach to prioritising requests for NICE Scientific Advice19/07/2021 14:15:00
Dr Jacoline Bouvy explains the new NICE Advice prioritisation process.
NICE to produce rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination09/07/2021 13:25:00
NHS England has asked NICE to develop a guideline on the management and follow up of blood clots and low platelet counts associated with COVID-19 vaccination.
NICE opens consultation on draft pelvic floor dysfunction guideline recommendations30/06/2021 14:15:00
NICE recently (28 June 2021) published its draft guideline on the prevention and non-surgical management of pelvic floor dysfunction and is seeking stakeholder comments on the draft recommendations.
NICE recommends adoption of absorbable stitches with antibacterial protection for use on the NHS29/06/2021 11:15:00
NICE estimates an average cost saving of £13.62 per patient to the NHS as a result of reduced surgical site infections compared with current standard absorbable stitches.
Consider mental health support for some people with acne, says NICE25/06/2021 15:05:00
In final guidance published today (25 June), NICE has for the first time recommended mental health support for people who are severely affected by their acne
NICE and PHE publish comprehensive draft guideline to tackle the health burden of smoking25/06/2021 12:15:00
Healthcare staff should give clear and up-to-date information on e-cigarettes to people who are interested in using them to stop smoking, according to draft NICE guideline recommendations out for consultation today. NICE worked with Public Health England to develop this guideline
Shared decision making underpins good healthcare18/06/2021 11:15:00
Shared decision making between service users and healthcare professionals is an integral part of healthcare, says NICE, in new guideline recommendations published yesterday.
Shared decision making recommendations will ensure people are at the heart of healthcare18/06/2021 08:15:00
NICE’s new guideline on shared decision making will help transform people’s experiences of health and social care. It will instil greater collaboration between professionals, patients and their families. It will pioneer a new climate and culture of putting people firmly at the heart of our healthcare system.